Although anti-PD1/PD-L1 immunotherapy shows durable response in other types of malignancies, its efficacy is limited to approximately 10% of GBM patients (11–13), thus highlighting the need for more effective and novel approaches, including the combination of additional IC inhibitors (ICIs) to target several IC pathways simultaneously. The gene discussed is CD274; the disease is glioblastoma.